Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2025; 16(7): 107256
Published online Jul 15, 2025. doi: 10.4239/wjd.v16.i7.107256
Chronic hepatitis B with type 2 diabetes mellitus: Association between glycemic control and liver fibrosis
Yan Luo, Rui Li, Jun Kang, Ben-Nan Zhao, Li-Juan Lan, Feng-Jiao Gao, Xiao-Xia Ren, Yan-Feng Zhu, Da-Feng Liu
Yan Luo, Yan-Feng Zhu, School of Public Health, Chengdu Medical College, Chengdu 610500, Sichuan Province, China
Rui Li, Jun Kang, Feng-Jiao Gao, Xiao-Xia Ren, Da-Feng Liu, The First Ward of Internal Medicine, Public Health Clinical Center of Chengdu, Chengdu 610066, Sichuan Province, China
Ben-Nan Zhao, Li-Juan Lan, Department of Internal Medicine, Public Health Clinical Center of Chengdu, Chengdu 610066, Sichuan Province, China
Co-first authors: Yan Luo and Rui Li.
Co-corresponding authors: Yan-Feng Zhu and Da-Feng Liu.
Author contributions: Luo Y and Li R contributed equally to this manuscript as co-first authors. Luo Y and Liu DF designed the research study; Zhu YF and Liu DF supervised the study and made equal contributions as co-corresponding authors. Luo Y, Li R, Kang J, Zhao BN, Lan LJ, Gao FJ, Ren XX, Zhu YF, and Liu DF acquired the data, analyzed and interpreted the data, drafted the manuscript, provided administrative, technical, or material support. All authors approved the final manuscript.
Supported by Natural Science Foundation of Sichuan Province, No. 2023NSFSC0682.
Institutional review board statement: This study was approved by the Ethics Committee of the Public Health Clinical Center of Chengdu, No. YJ-K2024-15-01.
Informed consent statement: As this is a retrospective study and the majority of patients could not be contacted, the requirement of written informed consent was waived by the hospital ethics committee.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All the data, models, or codes generated or used during the study are available from the corresponding author by request corresponding author.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Da-Feng Liu, MD, PhD, Chief Physician, Professor, The First Ward of Internal Medicine, Public Health Clinical Center of Chengdu, No. 18 Jingjushi Road, Jinjiang District, Chengdu 610066, Sichuan Province, China. ldf312@126.com
Received: March 20, 2025
Revised: April 30, 2025
Accepted: June 16, 2025
Published online: July 15, 2025
Processing time: 118 Days and 2.9 Hours
Core Tip

Core Tip: This study found that fasting blood glucose significantly mediated the progression of hepatic fibrosis in patients with both chronic hepatitis B and type 2 diabetes mellitus, via the alanine aminotransferase/aspartate aminotransferase pathway. Albumin and gamma-glutamyl transferase levels varied among groups with differing glycemic status, while fibrinogen, the international normalized ratio, serum ferritin, type III procollagen N-terminal peptide, aspartate aminotransferase, prothrombin time, and thromboplastin activity were associated with glycemic levels. These findings indicate that both hepatic impairment and coagulation dysfunction are influenced by glycemic control, and that stringent glycemic management along with the administration of hypoglycemic agents may lower the risk of fibrosis.